Outline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
|
|
- Felicity Paul
- 5 years ago
- Views:
Transcription
1 Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial evaluation Identifying candidates for therapy Therapeutic options Additional monitoring Who should be screened for HBV? Chronic Hepatitis B Individuals born in high (8%) or intermediate (2-7%) prevalence areas Asia, Africa, Middle East (except Israel), Spain, Eastern Europe, Central/South America Pregnant women Infants of HBsAg+ mothers, household contacts Behavioral contacts: HIV+, MSM, IVDU, inmates Renal dialysis patients Patients receiving immunosuppressive therapy Abnormal ALT of unknown cause Terrault, AASLD HBV Practice Guidance
2 Who should be screened for HBV? Worldwide prevalence of chronic HBV Individuals born in high (8%) or intermediate (2-7%) prevalence areas Asia, Africa, Middle East (except Israel), Spain, Eastern Europe, Central/South America Pregnant women Infants of HBsAg+ mothers, household contacts Behavioral contacts: HIV+, MSM, IVDU, inmates 2010 Census: % Asian Bay Area: 23% SF: 33% Renal dialysis patients Patients receiving immunosuppressive therapy Abnormal ALT of unknown cause Terrault, AASLD HBV Practice Guidelines Initial tests to determine HBV status Interpretation of tests Next steps Immunity HBsAb HBcAb HBsAg Interpretation Next Step HBV surface antigen (sag) HBV surface antibody (sab) HBV core antibody (cab) Not immune Vaccinate + Immune Nothing + + Immune Nothing + Prior exposure/ False(+) core Ab + Chronic infection Educate re: risk of reactivation Determine state of infection 2
3 Interpretation of tests Next steps Exposure HBsAb HBcAb HBsAg Interpretation Next Step Not immune Vaccinate + Immune Nothing + + Immune Nothing + Prior exposure/ False(+) core Ab + Chronic infection Educate re: risk of reactivation Determine state of infection Interpretation of tests Next steps Chronic HBsAb HBcAb HBsAg Interpretation Next Step Not immune Vaccinate + Immune Nothing + + Immune Nothing + Prior exposure/ False(+) core Ab + Chronic infection Educate re: risk of reactivation Determine state of infection Interpretation of tests Next steps Initial approach to the HBsAg+ patient HBsAb HBcAb HBsAg Interpretation Next Step Not immune Vaccinate + Immune Nothing STEP 2 STEP Immune Nothing + Prior exposure/ False(+) core Ab + Chronic infection Educate re: risk of reactivation Determine state of infection STEP 1 3
4 Initial approach to the HBsAg+ patient Initial approach to the HBsAg+ patient STEP 3 STEP 3 STEP 2 STEP 2 STEP 1 Fibrosis Stage Platelet count INR Albumin Abd U/S: liver contour, spleen size, portal vein STEP 1 Fibrosis Stage Platelet count INR Albumin Abd U/S: liver contour, spleen size, portal vein Risk Factors for Accelerated Disease HIV/HCV/HDV coinfection Heavy alcohol consumption Hepatitis A immunity vaccinate if not immune Initial approach to the HBsAg+ patient STEP 3 State of Infection for chronic (>6mo) HBV Chronic active If HBeAg(+): ALT 1-2x ULN If HBeAg(-): HBV DNA>2,000 IU/mL + ALT 1-2x ULN STEP 1 Fibrosis Stage Platelet count INR Albumin Abd U/S: liver contour, spleen size, portal vein STEP 2 Risk Factors for Accelerated Disease HIV/HCV/HDV coinfection Heavy alcohol consumption Hepatitis A immunity vaccinate if not immune State of Infection ALT HBV DNA HBV e antigen / antibody (See next slide) Chronic inactive ( carrier ) HBeAg(-), HBeAb(+) HBV DNA <2,000 IU/mL Persistently normal ALT (<20 for women, <30 for men) Resolved infection HBcAb(+), HBsAg(-) ndetectable HBV DNA ormal ALT (<20 for women, <30 for men) 4
5 State of Infection for chronic (>6mo) HBV Chronic active Refer to If HBeAg(+): ALT 1-2x ULN hepatology If HBeAg(-): HBV DNA>2,000 IU/mL + ALT 1-2x ULN Chronic inactive ( carrier ) HBeAg(-), HBeAb(+) HBV DNA <2,000 IU/mL Persistently normal ALT (<20 for women, <30 for men) Resolved infection HBcAb(+), HBsAg(-) Undetectable HBV DNA Normal ALT (<20 for women, <30 for men) State of Infection for chronic (>6mo) HBV Chronic active Refer to If HBeAg(+): ALT 1-2x ULN hepatology If HBeAg(-): HBV DNA>2,000 IU/mL + ALT 1-2x ULN Chronic inactive ( carrier ) HBeAg(-), HBeAb(+) yhbv DNA <2,000 IU/mL Persistently normal ALT (<20 for women, <30 for men) Resolved infection HBcAb(+), HBsAg(-) Undetectable HBV DNA Normal ALT (<20 for women, <30 for men) State of Infection for chronic (>6mo) HBV Chronic active Refer to If HBeAg(+): ALT 1-2x ULN hepatology If HBeAg(-): HBV DNA>2,000 IU/mL + ALT 1-2x ULN Chronic inactive ( carrier ) HBeAg(-), HBeAb(+) HBV DNA <2,000 IU/mL Persistently normal ALT (<20 for women, <30 for men) Resolved infection HBcAb(+), HBsAg(-) Undetectable HBV DNA Normal ALT (<20 for women, <30 for men) Monitor ALT/HBV DNA Q3mo x 1 yr, then Q6-12 mo State of Infection for chronic (>6mo) HBV Chronic active Refer to If HBeAg(+): ALT 1-2x ULN hepatology If HBeAg(-): HBV DNA>2,000 IU/mL + ALT 1-2x ULN Chronic inactive ( carrier ) HBeAg(-), HBeAb(+) HBV DNA <2,000 IU/mL Persistently normal ALT (<20 for women, <30 for men) Resolved infection HBcAb(+), HBsAg(-) Undetectable HBV DNA Normal ALT (<20 for women, <30 for men) Monitor ALT/HBV DNA Q3mo x 1 yr, then Q6-12 mo Consider HBV treatment if immunosuppressed. 5
6 Indications for anti-hbv treatment Indications for anti-hbv treatment Immune Active Infection HBeAg positive: ALT 2x ULN, HBV>20K IU HBeAg negative: HBV>2000u + ALT 2X ULN Immune Active Infection HBeAg positive: ALT 2x ULN, HBV>20K IU HBeAg negative: HBV>2000u + ALT 2X ULN Stage 2 fibrosis Liver biopsy Fibroscan Available at UCSF Hepatology! Covered by most insur. except Medi-Cal ($200) Indications for anti-hbv treatment Indications for anti-hbv treatment Immune Active Infection HBeAg positive: ALT 2x ULN, HBV>20K IU HBeAg negative: HBV>2000u + ALT 2X ULN Stage 2 fibrosis Liver biopsy Fibroscan Available at UCSF Hepatology! Covered by most insur. except Medi-Cal ($200) Immune Active Infection HBeAg positive: ALT 2x ULN, HBV>20K IU HBeAg negative: HBV>2000u + ALT 2X ULN Stage 2 fibrosis Liver biopsy Fibroscan Available at UCSF Hepatology! Covered by most insur. except Medi-Cal ($200) HBV core Ab + Undergoing immunosuppressive therapy Chemotherapy High dose corticosteroids Anti-TNF alpha History of other liver disease HIV/HCV/HDV Hepatocellular carcinoma Family history of cirrhosis or HCC HBV core Ab + Undergoing immunosuppressive therapy Chemotherapy High dose corticosteroids Anti-TNF alpha 6
7 1 st -line HBV Treatment Options 1 st -line HBV Treatment Options NucleoSide analog Mechanism NucleoTide analog 0.5 mg per day Dose 300 mg per day Reduce for egfr<50 Renal dosing Reduce for egfr<50 NucleoSide analog Mechanism NucleoTide analog 0.5 mg per day Dose 300 mg per day Reduce for egfr<50 Renal dosing Reduce for egfr<50 Headache, fatigue, dizziness, nausea (but generally very well tolerated) Side effects Nausea, headache, dizziness (but generally very well tolerated) Headache, fatigue, dizziness, nausea (but generally very well tolerated) Side effects Nausea, headache, dizziness (but generally very well tolerated) Lactic acidosis (rare) Adverse effects Fanconi s syndrome C Pregnancy Category B Lactic acidosis (rare) Adverse effects Fanconi s syndrome C Pregnancy Category B 1 st -line HBV Treatment Options 1 st -line HBV Treatment Options NucleoSide analog Mechanism NucleoTide analog 0.5 mg per day Dose 300 mg per day AASLD 2018 guidance suggests no Reduce for egfr<50 Renal dosing Reduce for egfr<50 preference b/n entecavir and Headache, fatigue, Nausea, headache, dizziness, tenofovir nausea (but regarding potential dizziness longterm (but generally Side effects generally very well risks of renal complications. very well tolerated) tolerated) Lactic acidosis (rare) Adverse effects Fanconi s syndrome C Pregnancy Category B NucleoSide analog Mechanism NucleoTide analog 0.5 mg per day Dose 300 mg per day Reduce for egfr<50 Renal dosing Reduce for egfr<50 Headache, fatigue, dizziness, nausea (but generally very well tolerated) Side effects Nausea, headache, dizziness (but generally very well tolerated) Lactic acidosis (rare) Adverse effects Fanconi s syndrome C Pregnancy Category B 7
8 Other HBV medications HCC screening criteria Lamivudine Adefovir Truvada (tenofovir/emtricitabine) HBVcAb positive prophylaxis Previously prescribed Low barrier to resistance Previously prescribed No longer available Not as effective as other medications HIV coinfection Lamivudine resistance HCC screening (abdominal U/S + AFP Q6mo) for: Population group Male >40 years Female >50 years Family history of HCC at any age African Cirrhosis Incidence of HCC % per year % per year Higher than without a family history HCC risk is high at any age 3-8% per year Bruix, AASLD HCC practice guidelines Monitoring HBV HBV: Key Points If on treatment: ALT and HBV DNA every 6 months If on tenofovir: Creatinine and phosphorus every 6 months (Fanconi s syndrome) Dose reductions needed with renal insufficiency for both entecavir and tenofovir If not on treatment: ALT/HBV DNA every 3 mo for the first year Then every 6 months if no indication for treatment HBeAg and HBeAb every year Optional: platelet count, albumin, and INR All patients from intermediate/high prevalence HBV countries or with behavioral risk factors should be screened Screening labs: HBsAb, HBcAb, HBsAg Initial work-up for HBsAg+ patient: State of infection: ALT, HBV DNA, HBeAg, HBeAb Stage of disease: Platelet, Albumin, INR, Abdominal ultrasound Risk factors for disease progression: HCV, HIV, HDV coinfection 1 st line treatment options are: entecavir, tenofovir HCC screening with abdominal ultrasound +/- AFP in: Males >40 years, females >50 years, all Africans, HCC fhx, cirrhotics 8
9 HCV: The Cure is Here!!!! Chronic Hepatitis C Who should be screened? Who should be screened? Individuals at high risk: IVDU current and past Recipients of clotting factors before 1987 or blood transfusions/organ transplant before July 1992 Patients on chronic hemodialysis Persons with HIV infection Current sexual partners of HCV-infected individuals CDC and USPSTF recommendations (2013): All individuals born between (50-70 yo) should be screened 45% are expected to have cirrhosis by 2020! Individuals at high risk: IVDU current and past Recipients of clotting factors before 1987 or blood transfusions/organ transplant before July 1992 Patients on chronic hemodialysis Persons with HIV infection Current sexual partners of HCV-infected individuals CDC and USPSTF recommendations (2013): All individuals born between (50-70 yo) should be screened 45% are expected to have cirrhosis by 2020! CDC MMWR 2012; Chou, Ann Intern Med Armstrong, Ann Intern Med CDC MMWR 2012; Chou, Ann Intern Med Armstrong, Ann Intern Med
10 Which patients should be evaluated for treatment? Commonly-used HCV regimens Everyone! (who is interested) Harvoni (ledipasvir / sofosbuvir) Epclusa (sofosbuvir / velpatasvir) Mavyret (glecaprevir / pibrentasvir) Vosevi (sofosbuvir / velpatasvir / voxilaprevir) Zepatier (elbasvir / grazoprevir) Highly successful! 94%+ rates of sustained virologic response Choice of treatment depends on Please send this information with referral HCV RNA HCV genotype Markers of liver disease severity Platelet Total bilirubin Albumin PT/INR Creatinine HCV Fibrosure / Fibrotest Abdominal ultrasound HIV Ag/Ab, HBV (sag, sab, cab) 10
11 HCV: Key Points Screen all individuals with at high risk for HCV transmission and/or born between (CDC) Screening test: HCV antibody. If positive: HCV RNA, HCV genotype, liver panel, creatinine Non-invasive staging: Plt, INR, Alb, complete abdominal U/S, HCV Fibrosure Many all-oral treatment regimens available, effective, and tolerable UCSF Hepatology has a dedicated HCV treatment team Thank you Jennifer C. Lai, MD, MBA Associate Professor Medicine In Residence Division of Gastroenterology & Hepatology UCSF Jennifer.lai@ucsf.edu 11
2013 UPDATES IN HEPATITIS B & C
2013 UPDATES IN HEPATITIS B & C Jennifer C. Lai, MD, MBA Division of Gastroenterology/Hepatology University of California, San Francisco Financial disclosures: none Outline: HBV & HCV Case-based presentations
More informationUpdates on Hepatitis B and Hepatitis C
Updates on Hepatitis B and Hepatitis C Bilal Hameed, MD Associate Professor of Medicine University of California San Francisco Chronic Hepatitis B Epidemiology and natural history Recommendation for screening
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationACTIVITY DISCLAIMER. Kurt Cook, MD, MSc DISCLOSURE. Audience Engagement System. Learning Objectives
On the Liver Disease Front Lines: Hepatitis A, B and C Prevention and Treatment Kurt Cook, MD, MSc ACTIVITY DISCLAIMER The material presented here is being made available by the American Academy of Family
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationCurrent Issues in Hepatitis B and C
Current Issues in Hepatitis B and C Rena Fox, MD Professor of Clinical Medicine Division of General Internal Medicine May-June 2018 Disclosures: Quality improvement project funded by Gilead Sciences, completed
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More information10/10/18. Hepatitis B and C: New Medications, New Hope and New Opportunities for Primary Care. Hepatitis B. Hepatitis B and C. I have no disclosures
Hepatitis B and C: New Medications, New Hope and New Opportunities for Primary Care I have no disclosures Rena Fox, MD Professor of Clinical Medicine Division of General Internal Medicine Hepatitis B and
More informationEmerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEnd Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC
End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationObjectives. Five Take Home Pearls. We Can Cure Hepatitis C. Hepatitis C Screening, Treatment and the Family Physician 10/15/2018
10/15/2018 Objectives Hepatitis C Screening, Treatment and the Family Physician Wayne Ghesquiere MD FRCPC Infectious Diseases & Internal Medicine Division of Infectious Diseases Victoria, BC At the end
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationPhysical Aspects of Substance Misuse in Older People. Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford
Physical Aspects of Substance Misuse in Older People Jane Collier Consultant Hepatology John Radcliffe Hospital Oxford Areas to cover Hepatitis C Curable disease New drugs (goodbye interferon) Drug Interactions
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationClinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17
Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of
More informationEAST LONDON INTEGRATED CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationTransmission of HCV in the United States (CDC estimate)
Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong
More informationAddress: City: State: ZIP code: Inferferon Product Requested (Include Strength):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationHepatitis C. No disclosures. 1. The USPSTF recommends Hepatitis C screening in which patient populations?
Hepatitis C Jennifer Acosta PA-C No disclosures 1. The USPSTF recommends Hepatitis C screening in which patient populations? a. All adults at least once b. Immigrants to the US and those over age 65 c.
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationIt is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:
Clinical Policy: (Mavyret) Reference Number: CP.CPA.285 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17
Clinical Policy: (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationChronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationHEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017
HEPATITIS C Whitney Dickson, PharmD, BCPS October 12 th, 2017 MY BACKGROUND Pharmacy School: University of California San Diego Pharmacy Practice Residency (PGY1): University of Illinois at Chicago HIV/Hep
More informationHepatitis C in Disclosures
Hepatitis C in 2018 Sandeep Mukherjee, MD CHI Health and Creighton University Medical Center Division of Gastroenterology Grant support: Abbvie Disclosures Speaker: Abbvie, Gilead, Merck Section editor
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationNew York State HCV Provider Webinar Series
New York State HCV Provider Webinar Series Treatment of HCV/HIV Co-Infection Dost Sarpel, MD Division of Infectious Disease Viral Hepatology Milford Regional Medical Center Objectives Review the epidemiology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationManagement of Hepatitis B
Management of Hepatitis B Background HBV is contracted either sexually or by blood to blood transmission. The combined prevalence of HBV and HCV is just over 2% in the UK. More than 95% of immune competent
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationArvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine
Arvind R. Murali, MD Assistant Professor of Medicine Gastroenterology & Hepatology Organ Transplant Center UIHC, Carver College of Medicine No financial disclosures No conflicts of interest No affiliations
More informationProfessional Practice Meeting February Hepatitis C
Professional Practice Meeting February 2018 Hepatitis C Hepatitis C Overview Hepatitis C Virus Enveloped, single-stranded RNA virus 6 main genotypes: Rapidly mutating virus makes vaccination design difficult
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Mavyret) Reference Number: CP.HNMC.39 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17
Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy
More informationCITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE
CITY & HACKNEY ELIC EAST LONDON INTEGRATED CARE MANAGEMENT OF CHRONIC HEPATITIS B IN PRIMARY CARE Chronic Hepatitis B virus (HBV) is an important public health problem globally and a leading cause of liver
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationHepatitis C ew Medications, New Hope and New. V. Opportunities for Primary Care. Outline. HCV Disease Outcomes in the US 9/21/2016
Hepatitis C ew Medications, New Hope and New Opportunities for Primary Care Primary Care Principles and Practice October 14, 2016 Disclosures: Grant support Gilead Sciences, Inc Quality improvement Systematized
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationOutline. HCV Disease Outcomes in the US. Hepatitis C: The New Landscape 5/24/16. Advances in Internal Medicine May 24, I have no disclosures
5/24/16 Hepatitis C: The New Landscape Advances in Internal Medicine May 24, 2016 I have no disclosures Rena K. Fo, MD Professor of Clinical Medicine, UCSF Outline I. Current HCV outcomes in the US II.
More informationPage 1 of 6. Hepatitis B Virus (HBV) PRESENTATION RECOMMENDED IMMMUNOSUPRESSIVE TREATMENT TEST RESULTS. Obtain baseline HBV DNA level
Hepatitis B Virus (HBV) PRESENTATION Medical history: Previous history of HBV On anti-hbv medications Hepatitis Screening and Management HBV and HCV Risk factors associated with HBV infection: Born in
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationPart I. Prior Authorization Criteria and Policy
Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled
More informationCurrent Status of HBV and Liver Transplant
Current Status of HBV and Liver HBV as Indication for Liver ation in U.S. Significant decrease in rate of wait listing for decompensated cirrhosis since 2003 (since s) No change in rate of wait listing
More informationHBV, HCV, HIV and Kidney Transplantation. Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania
HBV, HCV, HIV and Kidney Transplantation Simin Goral MD University of Pennsylvania Medical Center Philadelphia, Pennsylvania Objectives Prevalence of hepatitis B (HBV), hepatitis C (HCV) and human immunodeficiency
More informationWHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT
WHEN HCV TREATMENT IS DEFERRED WV HEPC ECHO PROJECT October 13, 2016 Reminder - treatment is recommended for all patients with chronic HCV infection Except short life expectancies that cannot be remediated
More informationHepatitis A, B, and Mostly C
Hepatitis A, B, and Mostly C Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Leaning Objectives Burden of viral hepatitis Hepatitis A A little bit about hepatitis E Hepatitis B Hepatitis
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: March 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationHepatitis C Policy Discussion
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationViral hepatitis Blood Born hepatitis. Dr. MONA BADR Assistant Professor College of Medicine & KKUH
Viral hepatitis Blood Born hepatitis Dr. MONA BADR Assistant Professor College of Medicine & KKUH Outline Introduction to hepatitis Characteristics of viral hepatitis Mode of transmission Markers of hepatitis
More informationHBV/HCV COINFECTIONS IN PATIENTS WITH HIV. Dr Reena Harania MBBS, MRCP, MSc Infectious Disease
HBV/HCV COINFECTIONS IN PATIENTS WITH HIV Dr Reena Harania MBBS, MRCP, MSc Infectious Disease Adults and children estimated to be living with HIV as of end 2005 North America 1.2 million [650 000 1.8 million]
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationManagement of HBV in KidneyTransplanted Patients Dr.E.Nemati
Management of HBV in KidneyTransplanted Patients Dr.E.Nemati Hepatitis B virus (HBV) infection Hepatitis B virus (HBV) infection confers a significantly negative impact on the clinical outcomes of kidney
More informationManagement of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER
Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines
More informationWorldwide Causes of HCC
Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationStaging liver disease
Staging liver disease A hepatologist, ID doc, primary care provider, and insurance executive go to a bar Slide 1 of 44 Staging liver disease A hepatologist, ID doc, primary care provider, and insurance
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationToronto Declaration: Strategies to control and eliminate viral hepatitis globally. A call for coordinated action
Toronto Declaration: Strategies to control and eliminate viral hepatitis globally A call for coordinated action Hepatitis B National Action Plan All countries should develop a national and/or regional
More informationViral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician
Viral Hepatitis: Dr Erana Gray General and Infectious Diseases Physician Outline: Virology HBV + pregnancy HCV + new treatments Cases Hepatitis Foundation HBV: virus HBsAg far in excess of complete virions,
More informationViral Hepatitis Update: Screening, Vaccination, and Treatment
Viral Hepatitis Update: Screening, Vaccination, and Treatment Alaska Maternal Child Health & Immunization Conference September 28, 2016 Prabhu Gounder, MD, MPH, FACP Medical officer, CDC Arctic Investigations
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationClinical dilemmas in HBeAg-negative CHB
Clinical dilemmas in HBeAg-negative CHB George V. Papatheodoridis Professor in Medicine & Gastroenterology Medical School of National & Kapodistrian University of Athens Director of Academic Department
More informationHepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider
Hepatitis C Pre-Treatment Assessment: The Role of the Primary and HCV Provider David C. Wolf, MD, FACP, FACG, AGAF, FAASLD Medical Director of Liver Transplantation Westchester Medical Center Professor
More information